Bank of New York Mellon Corp lowered its stake in shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) by 0.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,961 shares of the company’s stock after selling 92 shares during the period. Bank of New York Mellon Corp’s holdings in Aquinox Pharmaceuticals were worth $333,000 at the end of the most recent reporting period.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.15. During the same period last year, the business posted ($0.39) EPS.

ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Has $333,000 Position in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/bank-of-new-york-mellon-corp-has-333000-position-in-aquinox-pharmaceuticals-inc-nasdaqaqxp.html.

AQXP has been the topic of several analyst reports. Cantor Fitzgerald set a $28.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 9th. ValuEngine upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Thursday, May 11th. Finally, BidaskClub downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Aquinox Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $22.50.

In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $13.26, for a total transaction of $207,187.50. Following the transaction, the insider now owns 77,530 shares of the company’s stock, valued at approximately $1,028,047.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.70% of the stock is owned by insiders.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Want to see what other hedge funds are holding AQXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP).

Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.